
Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Buadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and ScienceFellowship, Blood & Bone Marrow Transplant, 2002 - 2003
University of MarylandFellowship, Hematology and Medical Oncology, 1999 - 2002
St Agnes HealthCareResidency, Internal Medicine, 1996 - 1999
University of Science and Technology SOMClass of 1991
School of Medical Sciences, University of Science and TechnologyB.S., 1984 - 1987
Certifications & Licensure
MN State Medical License 2002 - 2026
MD State Medical License 1999 - 2008
TN State Medical License 2004 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017
- CMS Meaningful Use Stage Stage 2 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
- CMS Meaningful Use Stage Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
Publications & Presentations
PubMed
- Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.Saurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, Horatiu Olteanu, Francis Buadi
Blood Cancer Journal. 2026-01-03 - Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary p...Tamer Hellou, Shaji K Kumar, Samhar Samer Alouch, Adrian Almodovar-Diaz, Angela Dispenzieri
Blood Cancer Journal. 2025-12-27 - Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort Study.Yoshito Nishimura, Thomas M Habermann, Morie A Gertz, Luis Porrata, Patrick B Johnston
Blood Advances. 2025-12-24
Journal Articles
- Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple MyelomaS Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
- Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell TransplantationNelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
- Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of RelapseAngela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
Books/Book Chapters
Abstracts/Posters
- A phase ll study (px-171-003-a1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myelomaSiegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi FK, Reu F, Somlo G, Zonder J, Stewart AK, Stad..., Onkologie, 10/1/2013
- Prediction of poor mobilization of autologous cd34+cells in multiple myeloma (mm): implications for risk-stratificationCosta LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Kang Y, Gertz MA, Stuart RK, Kumar SK, Transfusion, 9/1/2013
- A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (rrmm)Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi FK, Reu FJ, Somlo G, Zonder J, Song K, Stewa..., Br J Haematol, 4/1/2013
Lectures
- Hematologic Malignancies: New Therapies and the Evolving Role of TransplantMayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013
- Hematologic Malignancies: New Therapies and the Evolving Role of TransplantMayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013
Other
- Vital statistics, maternal mortality and causes of childhood mortality in the Tanoso district, Brong Ahafo region, Ghana (Thesis)Buadi FK, School of Medical Sciences, University of Science and Technology
Kumasi, Ghana - 8/1/1990 - Polyclonal HypergammaglobulinemiaBuadi FK, Ask Mayo Expert
http://javaprod.mayo.edu/ame/openTopic?collection=1&topicID=4592
Press Mentions
Comprehensive Care for a Complex Diagnosis Offers New HopeApril 22nd, 2019
Mayo Clinic Researchers Identify TherapyMarch 9th, 2017
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









